Allopurinol hypersensitivity syndrome: a review

OBJECTIVE: To review the pathophysiology, pathology, and clinical findings of allopurinol hypersensitivity syndrome (AHS), an infrequent but life-threatening adverse effect of allopurinol therapy. DATA SOURCES: A MEDLINE search (key terms hepatitis, interstitial nephritis, severe hypersensitivity, severe toxicity, vasculitis, toxic epidermal necrolysis, Lyell's syndrome, erythema multiforme, and Stevens-Johnson syndrome) was used to identify cases reported in the literature through the end of 1990. STUDY SELECTION: All cases evaluated met Singer and Wallace's diagnostic criteria for AHS. DATA EXTRACTION: We extracted data from 101 cases of AHS reported in the literature. The following information, when available, was analyzed: (1) patient data (age, gender, medical history), (2) treatment data (daily dosage of allopurinol, duration of treatment, indications, concomitant medications, and (3) adverse-event data. DATA SYNTHESIS: Patients were mostly middle-aged men with hypertension and/or renal failure receiving excessive doses of allopurinol primarily for asymptomatic hyperuricemia. Cutaneous rash and fever were the most common clinical findings. CONCLUSIONS: Although the pathophysiologic pathway leading to the development of AHS is unknown, it probably involves an immunologic mechanism following allopurinol accumulation in patients with poor renal function. Our findings suggest that the accepted diagnostic criteria for AHS may be too broad, and we recommend the application of more restrictive criteria. There is no effective treatment for AHS. The use of allopurinol only for accepted indications and in dosages adjusted for a patient's renal function may be the only means of minimizing the incidence of AHS.

This article has been cited by other articles:

				S. P Bruce Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout Ann. Pharmacother., December 1, 2006; 40(12): 2187 - 2194. [Abstract] [Full Text] [PDF]

				S. Sutaria, R. Katbamna, and M. Underwood Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review Rheumatology, November 1, 2006; 45(11): 1422 - 1431. [Abstract] [Full Text] [PDF]

				P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF]

				M. A Raebel, D. L McClure, S. R Simon, K A. Chan, A. C Feldstein, M. J Gunter, J. E. Lafata, L. Harrold, W. W Nelson, and R. Platt Frequency of Serum Creatinine Monitoring During Allopurinol Therapy in Ambulatory Patients Ann. Pharmacother., March 1, 2006; 40(3): 386 - 391. [Abstract] [Full Text] [PDF]

				A. Gutierrez-Macias, E. Lizarralde-Palacios, P. Martinez-Odriozola, and F. Miguel-De la Villa Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia BMJ, September 17, 2005; 331(7517): 623 - 624. [Full Text] [PDF]

				S.-C. Chao, C.-C. Yang, and J. Y.-Y. Lee Hypersensitivity Syndrome and Pure Red Cell Aplasia Following Allopurinol Therapy in a Patient with Chronic Kidney Disease Ann. Pharmacother., September 1, 2005; 39(9): 1552 - 1556. [Abstract] [Full Text] [PDF]

				S.-I. Hung, W.-H. Chung, L.-B. Liou, C.-C. Chu, M. Lin, H.-P. Huang, Y.-L. Lin, J.-L. Lan, L.-C. Yang, H.-S. Hong, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol PNAS, March 15, 2005; 102(11): 4134 - 4139. [Abstract] [Full Text] [PDF]

				A. Fukunari, K. Okamoto, T. Nishino, B. T. Eger, E. F. Pai, M. Kamezawa, I. Yamada, and N. Kato Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic Acid]: A Potent Xanthine Oxidoreductase Inhibitor with Hepatic Excretion J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 519 - 528. [Abstract] [Full Text] [PDF]

				E. N Liberopoulos, G. L Liamis, and M. S Elisaf Possible Cefotaxime-Induced Stevens-Johnson Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 812 - 814. [Abstract] [Full Text] [PDF]

				M. D. Feher, A. L. Hepburn, M. B. Hogarth, S. G. Ball, and S. A. Kaye Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout Rheumatology, February 1, 2003; 42(2): 321 - 325. [Abstract] [Full Text] [PDF]

				L. M. Sommers and R. B. Schoene Allopurinol Hypersensitivity Syndrome Associated With Pancreatic Exocrine Abnormalities and New-Onset Diabetes Mellitus Arch Intern Med, May 27, 2002; 162(10): 1190 - 1192. [Full Text] [PDF]

				J Vazquez-Mellado, E M. Morales, C Pacheco-Tena, and R Burgos-Vargas Relation between adverse events associated with allopurinol and renal function in patients with gout Ann Rheum Dis, October 1, 2001; 60(10): 981 - 983. [Abstract] [Full Text] [PDF]

				S. J. KELLY, M. DELNOMDEDIEU, M. I. OLIVERIO, L. D. WILLIAMS, M. G. P. SAIFER, M. R. SHERMAN, T. M. COFFMAN, G. A. JOHNSON, and M. S. HERSHFIELD Diabetes Insipidus in Uricase-Deficient Mice: A Model for Evaluating Therapy with Poly(Ethylene Glycol)-Modified Uricase J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1001 - 1009. [Abstract] [Full Text]

				E. Pascual Management of crystal arthritis Rheumatology, October 1, 1999; 38(10): 912 - 916. [Full Text] [PDF]

				Y. Suzuki, R. Inagi, T. Aono, K. Yamanishi, and T. Shiohara Human Herpesvirus 6 Infection as a Risk Factor for the Development of Severe Drug-Induced Hypersensitivity Syndrome Arch Dermatol, September 1, 1998; 134(9): 1108 - 1112. [Abstract] [Full Text] [PDF]

				A Kumar, N Edward, M I White, P W Johnston, and G R D Catto Lesson of the Week: Allopurinol, erythema multiforme, and renal insufficiency BMJ, January 20, 1996; 312(7024): 173 - 174. [Full Text]